New drug Spinosad
Has anyone used spinosad? Does it really kill scabies eggs? Were you able to cure yourself with it alone? How can it be supplied to other countries?
Has anyone used spinosad? Does it really kill scabies eggs? Were you able to cure yourself with it alone? How can it be supplied to other countries?
Dear researchers, parasitologists, dermatologists, and vaccine-development specialists,
We are calling on the scientific community to make the development of a vaccine against scabies a research priority.
Scabies is caused by the parasitic mite Sarcoptes scabiei and remains a significant global health problem. Scientific literature has already highlighted the need for vaccine development, while reduced susceptibility to some existing acaricidal treatments is an increasing concern. At present, however, there is no licensed human vaccine against scabies.
What we propose
We propose launching an accelerated international research program, ScabiVax-NG, focused on developing a multicomponent vaccine that targets several stages of the mite’s life cycle:
egg → larva → nymph → adult mite → reproduction.
Particular attention should be given to antigens associated with:
egg development and hatching;
mite feeding;
immune evasion;
larval and nymphal development;
reproduction of adult mites.
There is already preliminary experimental evidence supporting this direction. In a rabbit study, a combination of three recombinant S. scabiei proteins — serpin, CLP5, and CLP12 — produced significant protection and substantially reduced mite numbers.
Proposed six-month research phase
We are not asking researchers to bypass the necessary safety requirements. We are asking for the research phase to be accelerated as much as scientifically and ethically possible.
Month 1: Analyze the S. scabiei genome and proteome and identify a panel of promising vaccine antigens.
Months 2–3: Experimentally evaluate the most promising antigens and determine their ability to induce a specific immune response.
Months 3–4: Develop several multicomponent vaccine candidates.
Months 4–6: Conduct preclinical evaluation of the leading candidates, including their ability to reduce mite survival, reproduction, and completion of the life cycle.
The main objective
Within six months, the goal should not be to promise a finished vaccine for public use. The goal should be to identify a scientifically validated lead vaccine candidate that can immediately proceed to the next stages of preclinical and clinical development.
Vaccine development should complement existing treatments, not replace them.
We urge the scientific community, universities, government institutions, and pharmaceutical companies to combine resources and expertise to address this problem.
Scabies is a parasitic disease for which humanity still has no vaccine. It is time to make vaccine development a priority.
Proposed goal:
ScabiVax-NG — a next-generation vaccine against Sarcoptes scabiei, designed to disrupt the mite’s life cycle and prevent reinfestation.
We need not promises, but an urgent scientific program, funding, and international collaboration.